Cytosorbents Crp Stock Filter Stocks by Fundamentals
| CTSO Stock | USD 1.04 0.01 0.97% |
Cytosorbents Crp fundamentals help investors to digest information that contributes to Cytosorbents Crp's financial success or failures. It also enables traders to predict the movement of Cytosorbents Stock. The fundamental analysis module provides a way to measure Cytosorbents Crp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytosorbents Crp stock.
Cytosorbents | Shares Owned by Institutions |
Cytosorbents Crp Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cytosorbents Crp from analyzing Cytosorbents Crp's financial statements. These drivers represent accounts that assess Cytosorbents Crp's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytosorbents Crp's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 309.4M | 181.7M | 67.5M | 49.6M | 44.6M | 42.4M | |
| Enterprise Value | 239.0M | 143.4M | 63.6M | 53.8M | 48.4M | 93.7M |
Cytosorbents Crp Institutional Holders
Institutional Holdings refers to the ownership stake in Cytosorbents Crp that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cytosorbents Crp's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cytosorbents Crp's value.| Shares | Ubs Group Ag | 2024-12-31 | 144.9 K | Advisor Group Holdings, Inc. | 2024-12-31 | 122.4 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 106.6 K | Northern Trust Corp | 2024-12-31 | 91.6 K | Renaissance Technologies Corp | 2024-12-31 | 88 K | Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 60.6 K | Kestra Advisory Services, Llc | 2024-12-31 | 55 K | Engineers Gate Manager Lp | 2024-12-31 | 52.8 K | Raymond James & Associates | 2024-09-30 | 50 K | Avenir Corporation | 2024-12-31 | 3.1 M | Skylands Capital, Llc | 2024-12-31 | 2.8 M |
Cytosorbents Fundamentals
| Return On Equity | -1.18 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (0.49) % | ||||
| Operating Margin | (0.46) % | ||||
| Current Valuation | 85.96 M | ||||
| Shares Outstanding | 62.35 M | ||||
| Shares Owned By Insiders | 9.72 % | ||||
| Shares Owned By Institutions | 29.71 % | ||||
| Number Of Shares Shorted | 1.95 M | ||||
| Price To Earning | (16.30) X | ||||
| Price To Book | 4.99 X | ||||
| Price To Sales | 1.69 X | ||||
| Revenue | 36.35 M | ||||
| Gross Profit | 23.67 M | ||||
| EBITDA | (29.18 M) | ||||
| Net Income | (28.51 M) | ||||
| Cash And Equivalents | 30.16 M | ||||
| Cash Per Share | 0.69 X | ||||
| Total Debt | 18.31 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 0.24 X | ||||
| Cash Flow From Operations | (21.66 M) | ||||
| Short Ratio | 12.56 X | ||||
| Earnings Per Share | (0.36) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 186 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 63.59 M | ||||
| Total Asset | 53.26 M | ||||
| Retained Earnings | (282.51 M) | ||||
| Working Capital | 11.16 M | ||||
| Current Asset | 9.05 M | ||||
| Current Liabilities | 5 M | ||||
| Net Asset | 53.26 M |
About Cytosorbents Crp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytosorbents Crp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytosorbents Crp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytosorbents Crp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Cytosorbents Crp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytosorbents Crp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytosorbents Crp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytosorbents Crp Stock: Check out Cytosorbents Crp Piotroski F Score and Cytosorbents Crp Altman Z Score analysis. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.36) | Revenue Per Share | Quarterly Revenue Growth 0.066 | Return On Assets | Return On Equity |
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.